Vassiliki Bekou Amanda Büchau Michael J Flaig Thomas Ruzicka Michael Hogardt
10.1186/1471-5945-11-3
BMC Dermatol
2011 Jan 26;11:3.
CC BY
https://pubmed.ncbi.nlm.nih.gov/21269422/
IgA Deficiency / complications Mycobacterium Infections / complications Mycobacterium Infections, Nontuberculous / complications Mycobacterium haemophilum / isolation & purification Mycobacterium kansasii / isolation & purification Skin Diseases, Bacterial / complications
IgA Deficiency / complications Mycobacterium Infections / complications Mycobacterium Infections, Nontuberculous / complications Mycobacterium haemophilum / isolation & purification Mycobacterium kansasii / isolation & purification Skin Diseases, Bacterial / complications Case Reports Anti-Bacterial Agents / therapeutic use Biopsy Clarithromycin / administration & dosage Clarithromycin / therapeutic use Drug Therapy, Combination Ethambutol / administration & dosage Ethambutol / therapeutic use Humans Immunocompromised Host Male Middle Aged Mycobacterium Infections / immunology Mycobacterium Infections / microbiology Mycobacterium Infections / pathology Mycobacterium Infections, Nontuberculous / drug therapy Mycobacterium Infections, Nontuberculous / immunology Mycobacterium Infections, Nontuberculous / microbiology Mycobacterium Infections, Nontuberculous / pathology Mycobacterium haemophilum / growth & development Mycobacterium kansasii / growth & development Rifabutin / administration & dosage Rifabutin / therapeutic use Skin Diseases, Bacterial / drug therapy Skin Diseases, Bacterial / immunology Skin Diseases, Bacterial / microbiology Skin Diseases, Bacterial / pathology Anti-Bacterial Agents Rifabutin Ethambutol Clarithromycin
PMC3038168
21269422
Cutaneous infection by Mycobacterium haemophilum and kansasii in an IgA-deficient man
2011